Citius Pharmaceuticals
CTXR
16 hedge funds and large institutions have $1.09M invested in Citius Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
414% more capital inflows, than outflows
Capital inflows: $344K | Capital outflows: $66.8K
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
23% more funds holding
Funds holding: 13 → 16 (+3)
0.25% less ownership
Funds ownership: 2.14% → 1.89% (-0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$100K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$85.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38K |
| 4 |
Miller Investment Management
West Conshohocken,
Pennsylvania
|
+$28.3K |
| 5 |
Virtu Financial
New York
|
+$25.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tower Research Capital (TRC)
New York
|
-$21.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 3 |
Two Sigma Securities
New York
|
-$12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 5 |
Orion Portfolio Solutions
Omaha,
Nebraska
|
-$4K |
CTXR Hedge Fund Activity: Q3 2020 in Review
16 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2020, worth a combined $1.09M — up 0.46% from $1.09M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CTXR positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $100K. The largest seller was Tower Research Capital (TRC), cutting an estimated $21.8K.
- 16 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2020, up from 13 in Q2 2020.
- Funds reported $1.09M of Citius Pharmaceuticals stock for Q3 2020, up 0.46% quarter-over-quarter.
- 8 funds opened new Citius Pharmaceuticals positions in Q3 2020 and 4 closed out, a net change of +4 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2020 was Sabby Management, an estimated $100K added.
- The largest Citius Pharmaceuticals seller in Q3 2020 was Tower Research Capital (TRC), an estimated $21.8K sold.
Based on aggregated 13F filings for Q3 2020.